key: cord-1011274-01nptx6n
authors: Thorne, Lucy G; Reuschl, Ann‐Kathrin; Zuliani‐Alvarez, Lorena; Whelan, Matthew V.X.; Turner, Jane; Noursadeghi, Mahdad; Jolly, Clare; Towers, Greg J
title: SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation
date: 2021-06-07
journal: EMBO J
DOI: 10.15252/embj.2021107826
sha: 77f77adb56eb854839c18da998af69c5030127f0
doc_id: 1011274
cord_uid: 01nptx6n

SARS‐CoV‐2 infection causes broad‐spectrum immunopathological disease, exacerbated by inflammatory co‐morbidities. A better understanding of mechanisms underpinning virus‐associated inflammation is required to develop effective therapeutics. Here we discover that SARS‐CoV‐2 replicates rapidly in lung epithelial cells despite triggering a robust innate immune response through activation of cytoplasmic RNA‐sensors RIG‐I and MDA5. The inflammatory mediators produced during epithelial cell infection can stimulate primary human macrophages to enhance cytokine production and drive cellular activation. Critically, this can be limited by abrogating RNA sensing, or by inhibiting downstream signalling pathways. SARS‐CoV‐2 further exacerbates the local inflammatory environment when macrophages or epithelial cells are primed with exogenous inflammatory stimuli. We propose that RNA sensing of SARS‐CoV‐2 in lung epithelium is a key driver of inflammation, the extent of which is influenced by the inflammatory state of the local environment, and that specific inhibition of innate immune pathways may beneficially mitigate inflammation‐associated COVID‐19.

This article is protected by copyright. All rights reserved

In order to investigate innate immune responses to SARS-CoV-2, we first sought a producer cell line that did not respond to the virus, thereby allowing production of virus stocks free of inflammatory cytokines. As adaptive mutations have been reported during passage of the virus in Vero.E6 cells (Davidson et al, 2020; Ogando et al, 2020) , we selected human gastrointestinal Caco-2 cells, which express the SARS-CoV-2 receptor ACE2 and entry factors TMPRSS2/4 ( Figure EV1A , B) and are naturally permissive (Stanifer et al, 2020) . We found that Caco-2 support high levels of viral production ( Figure EV1C , D), but not virus spread (<15% cells infected) ( Figure EV1E , F). Importantly, they do not mount a detectable innate response to SARS-CoV-2 over 72 hpi at a range of multiplicities of infection (MOIs), as evidenced by a lack of interferon stimulated gene induction (ISG) ( Figure EV1G ). They are also broadly less responsive to innate immune agonists than lung epithelial Calu-3 cells (compare Figure EV1H -Caco-2 and Figure EV1I -Calu-3). Caco-2 cells were therefore used to produce SARS-CoV-2 stocks uncontaminated by inflammatory cytokines.

Comparatively, lung epithelial Calu-3 cells express high levels of receptor ACE2, and entry co-factors TMPRSS2 and TMPRSS4 ( Figure EV1A and B) (Hoffmann et al, 2020; Zang et al, 2020) , and are innate immune competent ( Figure Figure EV2B ). Infectious virus was evident in supernatants by 5 hpi at the highest MOI and peaked between 10-48 hpi, depending on MOI ( Figure 1E , Figure EV2C ). A pronounced innate immune response to infection followed the peak of viral replication, evidenced by induction of cytokines (IL-6, TNF), chemokines (CCL2, CCL5) and type I and III IFNs (IFN, IFN1/3) measured by and Figure EV2D -F).

This article is protected by copyright. All rights reserved This was accompanied by an IFN-stimulated gene (ISG) expression signature (CXCL10, IFIT1, IFIT2, MxA) ( Figure 1H and Figure EV2D -F). Gene induction was virus dose-dependent at 24 hpi, but equalised across all MOIs by 48 hpi, as the antiviral response to low-dose virus input maximised.

These data show that infected lung epithelial cells can be a direct source of inflammatory mediators.

We were surprised that SARS-CoV-2 replicated so efficiently in Calu-3 despite innate immune responses including IFN and ISG expression because coronaviruses, including SARS-CoV-2 are reported to be IFN sensitive (Stanifer et al., 2020) . Indeed, recombinant Type I IFN, but not type II or type III IFNs, effectively reduced SARS-CoV-2 replication if Calu-3 cells were treated prior to infection ( Figure 1I -K, Figure EV2G and H). However, Type I IFN had little effect on viral replication when added two hours after infection (Figure 1 I-K). Thus, the IFN response induced in infected lung epithelial Calu-3 cells appears too late to suppress SARS-CoV-2 replication in this system. To determine if viral exposure dose influences the race between viral replication and IFN, we infected cells at a 100x lower dose (MOI 0.0004 TCID50/cell) and observed a longer window of opportunity for exogenous Type I IFN to restrict viral replication (Figure 1 I-K). This is consistent with the hypothesis that high-dose infection can overcome IFN-inducible restriction.

To understand the apparent disconnect in the kinetics between innate immune activation and viral replication, we used single-cell imaging to measure nuclear localisation of activated inflammatory transcription factors NF-B p65 and IRF3, which mediate multiple PRR-signalling cascades. NF-B p65 nuclear translocation coincided with cells becoming N protein positive and a change was evident from 5 hpi (Figure 2A and B, Figure EV3A ). The timing of NF-B p65 translocation was dependant on the viral dose, from 5 hpi for the highest MOI (2 TCID50/cell, Figure EV3 ), between 5 -10 hpi for MOIs 0.4 and 0.04 (Figures 2A and B, Figure EV3 ), and 24 -48 hpi for MOI 0.004 ( Figure EV3 ). IRF3 activation was also virus dose dependent but did not maximise until 72 hpi, later than NF-B (Figures 2C and D, Figure EV3 ), and we observed a more modest shift in IRF3 nuclear intensity compared to

This article is protected by copyright. All rights reserved NF-B throughout infection. These data are consistent with the requirement of a threshold of viral RNA replication to induce transcription factor translocation and innate immune activation, and suggest that SARS-CoV-2 may antagonise IRF3 activation to a greater extent than NF-B. Although small variation in NF-B p65 and IRF3 nuclear intensity was observed in N negative cells, we did not see the same large increases sustained throughout the timecourse as in N positive cells, consistent with direct activation of NF-B p65 and IRF3 by virus replication ( Figure EV3 ).

Supporting the observation of activation of NF-B p65 and IRF3 activation by SARS-CoV-2 infection, single cell fluorescence in situ hybridisation (FISH) analysis of IL-6 mRNA (a prototypic NF-B regulated cytokine), showed increased IL-6 transcripts uniquely in N-positive infected cells, appearing at 6 hpi and peaking at 24hpi ( Figure 2E and F, Figure EV4A ). IFIT1 transcripts (a prototypic ISG) measured by FISH also demonstrated rapid induction in N-positive cells with increased signal from at 6 hpi ( Figure 2G and H). Strikingly, IFIT1 mRNA was not highly induced in N-negative bystander cells consistent with defective interferon responses failing to induce ISGs and a timely antiviral state in uninfected cells ( Figure 2H ). As a control for these changes, we show that GAPDH transcripts did not change ( Figure EV4B ). Secretion of pro-inflammatory chemokine CXCL10, and cytokine IL-6, followed gene expression and were detected from 24 hpi ( Figure 2I and J, Figure   EV4C ). Further analysis revealed increases in lactate dehydrogenase (LDH) in infected cell supernatants from 48 hpi, equal across all MOIs, indicative of pro-inflammatory cell death ( Figure   2K , EV4D). Importantly cytokine secretion had also equalised across MOIs from 24 hpi ( Figure 2I and J). LDH release paralleled loss of the epithelial monolayer integrity ( Figure 1C ) and cell death ( Figure   2L , Figure EV4E and F) accounting for the reduction in cytokine secretion at 72 hpi ( Figures 2I and J) .

To determine the mechanism of virus sensing by innate pathways, we first confirmed that viral RNA replication is required for innate immune activation. Inhibition of viral RNA replication, with polymerase inhibitor Remdesivir, abrogated pro-inflammatory and ISG gene expression in a dosedependent manner ( Figure 3A -D). Critically, Remdesivir was only effective if added prior to, or at the

This article is protected by copyright. All rights reserved time of infection, consistent with a requirement for metabolism to its active tri-phosphorlyated form (Eastman et al, 2020) 

Inflammatory gene induction dependent on viral genome replication suggested that an RNA sensor activates this innate response. Both genomic and subgenomic SARS-CoV-2 RNAs are replicated via double stranded intermediates in the cytoplasm . Accordingly, we detected cytoplasmic dsRNA at 5 hpi in Calu-3 cells, preceding N positivity ( Figure 3I (Hornung et al, 2006; Kato et al, 2006; Rehwinkel et al, 2010; Wu et al, 2013) .

Intriguingly, unlike RIG-I, MDA5 was not required for induction of NF-B-sensitive genes IL-6 or TNF, consistent with differences in downstream consequences of RIG-I and MDA5 activation ( Figure 3N and O) (Brisse & Ly, 2019) . Abrogating SARS-CoV-2 sensing via MDA5 and MAVS depletion also reduced cell death, suggesting cell death is mediated by the host response rather than direct virusinduced damage ( Figure 3P ). Notably, sensor depletion did not strongly increase viral RNA levels ( Figure 3Q ), or the amount of released infectious virus ( Figure 3R ), confirming that innate immune activation via RNA sensing did not potently inhibit viral replication.

As a complementary approach to mapping SARS-CoV-2-induced innate immune activation, and to assess the potential of specific immunomodulators to impact inflammatory responses and viral replication, we examined the effect of inhibiting NF-B activation using IK- kinase (IKK-) inhibitors TPCA-1 and PS1145. IKK- is responsible for NF-B p65 activation by phosphorylation following PRR signalling. Induction of ISGs and IL-6 was inhibited by TPCA-1, and with slightly reduced potency PS1145 ( Figure 4A -C, Figure EV5A and B). Inhibiting Janus kinase (JAK) with Ruxolitinib, to prevent Accepted Article JAK signalling downstream of the Type I IFN receptor (IFNAR), also suppressed SARS-CoV-2 induced ISGs, but not NF-B-sensitive IL-6 (Figure 4D-F and Figure EV5C ). Neither TPCA-1 nor Ruxolitinib treatment increased viral genome replication over a wide range of MOIs ( Figure 4G and H) or N positivity or virion production after single dose infection ( Figure EV5D -F). Importantly, NF-B and JAK inhibition significantly reduced cell death in infected cultures ( Figure 4I ). This is consistent with our earlier observation and with the notion that the innate immune response to infection is the main driver of lung epithelial cell damage. Our data thus far, show that SARS-CoV-2 infection of Calu-3 lung epithelial cells results in multi-pathway activation, driving pro-inflammatory and IFNmediated innate immune responses that are inadequate or arise too late to restrict virus. Critically, they also suggest that SARS-CoV-2 induced IFN and pro-inflammatory gene expression can be therapeutically uncoupled from viral replication.

Resident and recruited pro-inflammatory macrophages in the lungs are associated with severe COVID-19 disease (Bost et al., 2020; Liao et al, 2020; Pairo-Castineira et al., 2020; Szabo et al, 2020) .

We therefore asked whether macrophages can support SARS-CoV-2 infection and how they respond indirectly to infection, through exposure to conditioned medium from infected epithelial cells.

Importantly, neither primary monocyte-derived macrophages (MDM), nor PMA-differentiated THP-1 cells (as an alternative macrophage model), supported SARS-CoV-2 replication, evidenced by lack of increase in viral RNA and by the absence of N positive cells (Appendix Figure S1A -C). This is consistent with their lack of ACE2 and TMPRSS2 expression ( Figure EV1A Accepted Article experiments, MDM were exposed to equivalent numbers of viral genomes from the MAVS depleted, or inhibitor treated conditioned media (Appendix Figure S1D -F). To confirm that soluble mediators produced by infected Calu-3 cells were key in driving MDM activation, we pre-treated MDM with either anti-IFN  receptor 2 (IFNAR2) antibody or Ruxolitinib to inhibit IFN signalling during exposure to CoM. Both treatments reduced induction of ISG IFIT2 and CXCL10 in MDM. We also saw a trend towards decreasing CCL5 expression but this was not significant, suggesting other pro- 

Severe COVID-19 is associated with inflammatory co-morbidities suggesting that pre-existing inflammatory states lead to inappropriate immune responses to SARS-CoV-2 and drive disease (Lucas et al, 2020; Mehra et al, 2020; Williamson et al, 2020; Wolff et al, 2020; Zhang et al., 2020) .

Macrophages in particular are thought to potentiate inflammatory responses in the lungs of severe COVID-19 patients (Liao et al., 2020; Nicholls et al, 2003) and so we investigated whether inflammatory stimuli might directly exacerbate macrophage responses to SARS-CoV-2 alone ( Figure   6A -H). In these experiments we produced virus in Caco-2 and therefore it did not contain inflammatory cytokines ( Figure EV1G ). We detected low level innate immune activation after exposure of MDM to SARS-CoV-2 alone ( Figure 6B -H). However, when MDM were primed with 100 ng/ml LPS prior to exposure to SARS-CoV-2, we observed an enhanced response compared to exposure to virus or LPS alone, evidenced by significantly increased levels of ISGs ( Figure 6D and E) and pro-inflammatory CCL5 ( Figure 6C ). Of note, LPS alone induced IL-6 and inflammasomeassociated IL-1 expression and secretion and this was unaffected by virus exposure ( Figure 6F -H).

Exposure of MDM to SARS-CoV-2, prior to stimulation with LPS ( Figure 6I -P), also enhanced

This article is protected by copyright. All rights reserved macrophage inflammatory and ISG responses, but not IL-6 or IL-1 expression and secretion, compared to those detected with virus or LPS alone ( Figure 6J -P). Importantly, LPS treatment of MDM, before or after virus challenge, did not alter SARS-CoV-2 permissivity of MDM, evidenced by no change in the level of detectable viral E gene in MDM supernatants ( Figure 6B and J). Thus, the changes in MDM gene induction by virus after LPS treatment are due to differences in the MDM response to virus and not due to a difference in the amount of virus genome added or induction of viral gene expression.

Finally, we modelled the lung epithelial cell response to the cytokines observed in activated macrophages. We first selected IL-1, as it was produced by LPS-treated, LPS-primed virus-exposed and virus primed LPS-exposed MDM ( Figure 6G and H, O and P) and has been observed in severe COVID-19 patient lungs (Laing et al, 2020; Rodrigues et al, 2021) . Treatment of Calu-3 with IL-1 during infection significantly increased induction of both ISGs and pro-inflammatory cytokines, compared to their induction by virus alone ( Figure 6Q -T). The exception was IL-6, which was highly induced by virus even in the absence of IL-1 pre-treatment ( Figure 6S ). Next we treated Calu-3 cells with TNF, which is also produced by LPS-treated or primed MDM (Appendix Figure S2A and B) and implicated in severe COVID-19 (Chua et al., 2020; Mahase, 2020) , but found no enhancement of innate responses to SARS-CoV-2 (Appendix Figure S2C ). However, both IL-1 and TNF treatment increased virus-induced epithelial cell death ( Figure 6U and Appendix Figure S2D ), without impacting viral replication ( Figure 6V and Appendix Figure S2E ). Together, these data suggest that SARS-CoV-2 infection of lung epithelium can promote immune activation of inflammatory macrophages, via secretion of cytokines, chemokines and virus from infected cells, and that this can be exacerbated by a pre-existing pro-inflammatory state. This is consistent with the hypothesis that chronic inflammatory states, rather than enhanced viral replication, drive detrimental immune activation and/or cell death.

This article is protected by copyright. All rights reserved

We found that SARS-CoV-2 can replicate and spread effectively in lung epithelial Calu-3 cells over a wide range of inoculum doses despite inducing potent IFN responses and ISG expression. We propose that in the model system used here, innate immune activation occurs too late to suppress replication and attribute this to the virus deploying innate immune evasion and antagonism strategies early in infection. Indeed, coronaviruses replicate inside membranous vesicles, thought to protect viral RNA species from cytoplasmic sensing, and have complex capacity to antagonise innate immunity, including inhibition of MDA5 activation Xia et al, 2020) and preventing nuclear entry of inflammatory transcription factors (Banerjee et al, 2020; Miorin et al, 2020; Park & Iwasaki, 2020; Totura & Baric, 2012; Yuen et al, 2020) . Consistent with the literature, our data indicate that SARS-CoV-2 more effectively antagonises IRF3 activation and nuclear translocation than NF-B. Indeed, it is possible that the innate immune response and the secreted signals produced by infected cells are dysregulated by viral manipulation, and that this imbalanced response contributes to disease particularly in the context of underlying inflammatory pathology (Blanco-Melo et al., 2020; Giamarellos-Bourboulis et al, 2020; Lucas et al., 2020) .

We demonstrate that SARS-CoV-2 can be sensed by both RIG-I and MDA5 and that, through their signalling adaptor MAVS, these sensors drive inflammatory responses in infected Calu-3 cells ( Figure   7 ). Concordantly, both RIG-I and MDA5 have been implicated in sensing the murine coronavirus mouse hepatitis virus (Li et al, 2010; Roth-Cross et al, 2008) and MDA5 was recently shown to sense SARS-CoV-2 and trigger IFN production (Rebendenne et al, 2021; Yin et al, 2021) . Likewise, activation of dsRNA sensor PKR has also been observed during SARS-CoV-2 infection of other cell types . Interestingly, DNA sensing through cGAS-STING has also been reported to contribute to inflammatory responses (Neufeldt et al, 2020) , likely through sensing of self-DNA or cellular damage.

The eventual innate immune activation in Calu-3 cells is likely due to sensing of viral RNA when it accumulates to a level that overcomes sequestration and pathway inhibition by the virus, as well as to cellular stress responses to infection. Importantly, Calu-3 cells pre-treated with IFN resist infection illustrating that innate responses can suppress SARS-CoV-2 replication if an antiviral state is induced prior to infection, particularly with a low viral exposure dose.

This article is protected by copyright. All rights reserved Although SARS-CoV-2 RNA has been found associated with macrophages and monocytes from infected patients (Bost et al., 2020) , we found that macrophages did not support SARS-CoV-2 replication. However, they were sensitive to conditioned media from infected Calu-3 containing virus, IFNs and pro-inflammatory mediators, inducing high levels of chemokine and ISG mRNA and expression of activation markers CD86 and HLA-DR upon exposure. Crucially, it is the response of the Calu-3 cells to virus infection, via RNA sensing, that drives macrophage activation in these experiments, evidenced by suppression of activation after either MAVS depletion or NF-B (TPCA-1) or JAK inhibition (Ruxolitinib) in the infected Calu-3 cells. We found that IFNs produced by infected Calu-3 cells downstream of RNA sensing are key in driving MDM activation, evidenced by supression of macrophage activation with IFNAR antibody, although we expect other soluble mediators to contribute. This inflammatory role for IFN may explain how delayed IFN response could contribute to pathogenicity rather than viral clearance (Park & Iwasaki, 2020) .

A recent study suggested that sensing of abortive SARS-CoV-2 infection of macrophages may contribute to their activation (Zheng et al, 2021) . Our data do not rule out a role for detection of abortive replication. However, they suggest that inflammatory mediators produced from infected cells, perhaps with responses particularly skewed towards pro-inflammatory pathways after viral manipulation, are key to macrophage activation. Notably, exposure of macrophages to infected Caco2 supernatant, which contains virus but not significant levels of cytokine or IFN, did not strongly activate the macrophages. Indeed, our results show that it is important to distinguish between the effects of virus and the effects of cytokines in the viral prep. Here, we have achieved this by using Caco2 cells to produce virus without significant inflammatory cytokines and interferons and Calu3 to produce virus with a corresponding inflammatory secretome.

Importantly, inhibiting RNA sensing or pathway activation did not particularly increase viral replication, consistent with our observation that, in this model at least, virus-induced innate immune responses do not significantly inhibit SARS-CoV-2 replication. These observations highlight the

This article is protected by copyright. All rights reserved potential of immunomodulators in reducing SARS-CoV-2 driven inflammatory disease. Indeed, suppression of JAK1/2 signalling with Baricitinib, in SARS-CoV-2 infected macaques, significantly reduced macrophage recruitment and inflammatory signatures and preliminary data support its use in COVID-19 (Bronte et al, 2020) . These studies are consistent with epithelial-driven inflammation contributing to myeloid cell infiltration and the role of macrophages in exacerbating immune responses in COVID-19 (Giamarellos-Bourboulis et al., 2020; Hoang et al, 2020; Liao et al., 2020) . Our data provide a framework for dissecting immunomodulators as therapeutics and we propose that it is essential to test both immunomodulators, and direct acting antivirals, in innate-immune competent cells, rather than in Caco-2, Vero or other innate immune-inactive cell types, because the inevitable interactions between virus replication and innate immune pathways can influence drug efficacy and potency (Kim et al, 2019; Rasaiyaah et al, 2013; Sumner et al, 2020) .

A key question is how our experiments in Calu-3 cells inform understanding of COVID-19. We propose that by studying virus replication in innate immune competent permissive host cells we can probe the earliest interactions between the virus and the host that underpin subsequent inflammatory responses. Our data show that RNA sensing in infected Calu-3 cells creates a proinflammatory milieu capable of activating primary macrophages. Crucially the combined profile of pro-inflammatory mediators in this system mirrors that observed in COVID-19 in vivo (Bost et al., 2020; Laing et al., 2020; Szabo et al., 2020) and primary airway epithelial cells (Fiege et al, 2021) . We propose that in vivo it is the innate immune microenvironment in which the virus-host interaction occurs, and its consequent influence on immune activation, that determines disease outcome. This is consistent with our demonstration that exogenous inflammatory stimuli can drive a state in Calu-3 cells, and primary macrophages, that influences the response to virus, exacerbating inflammation. This link, between the immediate epithelial response to infection and external inflammatory signals, both amplified by macrophages, provides a plausible hypothesis to explain the association of severe COVID-19 with the presence of proinflammatory macrophages in broncheoalvolar lavage and patient lungs (Giamarellos-Bourboulis et al., 2020; Liao et al., 2020; Szabo et al., 2020) and inflammatory co-

This article is protected by copyright. All rights reserved morbidities (Mehra et al., 2020; Williamson et al., 2020; Wolff et al., 2020) , which could provide similar inflammatory stimulation.

It is remarkable how effective SARS-CoV-2 is in escaping human innate immune responses at the cellular level, despite being a recent zoonosis. Very low levels of adaptive change are consistent with adaptation to human replication prior to identification. Whether SARS-CoV-2 adapted in a nonhuman species prior to human infection, or whether adaptation in humans occurred before identification, remains unclear. One possibility is that coronaviruses replicate in a conserved niche, with regard to innate immune evasion, and thus are particularly good at zoonosis, perhaps evidenced by SARS-CoV-2 being preceded by SARS-CoV-1 and Middle Eastern Respiratory Syndrome virus (MERS), and apparent cross species transfer and transmission in distantly related species including humans, bats (Boni et al, 2020) , camels (Azhar et al, 2014) , civet cats (Wang & Eaton, 2007) and mink (Koopmans, 2020) . Viral disease is often driven by host immune mechanisms that have evolved to protect the host from death, a paradox that is particularly evident in COVID-19. Here we have taken a significant step towards explaining the consequences of SARS-CoV-2 infection of innate immune competent lung epithelial cells by illustrating how RNA sensing can directly drive potent inflammatory responses, irrespective of whether virus replication is suppressed. We propose that further studies addressing mechanisms of SARS-CoV-2 immune evasion and cytopathology, and the wider impact these have on epithelial-immune cell cross-talk, will inform development of effective therapeutics that are broadly active against zoonotic coronaviruses. 

This article is protected by copyright. All rights reserved macrophage colony stimulating factor (Peprotech). The medium was replaced after 3 days with RPMI with 5% FCS, removing any remaining non-adherent cells. Cells were infected or treated with conditioned media 3-4 days later. MDM were infected with virus diluted in RPMI, 5% FBS (estimated MOI 0.02 TCID50/cell). MDM were harvested at 24h or 48 hpi for gene expression analysis. For priming experiments, MDM were stimulated with 100 ng/mL of LPS (HC4046, Hycult Biotech) for 2h. Media was replaced and cells were exposed to SARS-CoV-2 as before, diluted in RPMI, 5% FBS. Cells were collected after 48h for analysis. Alternatively, cells were mock exposed or exposed to SARS-CoV-2 for 3 days and then stimulated with 100 ng/mL of LPS. Cells were harvested after 24h for analysis.

This article is protected by copyright. All rights reserved

In macrophage experiments, a minimum sample size of six independent experiments using cells derived from separate donors was used to give 90% power in order for a two-sided test to detect >two-fold differences between two groups with an estimated standard deviation of 0.5. °C. For conditioned media experiments, MDM were exposed to CoM as indicated, which was diluted 1:5 in RPMI, 5% FBS. After 6 hours, conditioned medium was replaced with RPMI, 5% FBS and cells

This article is protected by copyright. All rights reserved were harvested at 48 h for gene expression and surface marker expression analysis. MDM were treated where indicated during CoM exposure with either 2 M ruxolitinib (Biotechne) or 2.5 g/ml anti-IFNAR antibody (pbl Assay Science) or an isotype control IgG2A antibody (R&D).

RNA was extracted using RNeasy Micro Kits (Qiagen) and residual genomic DNA was removed from RNA samples by on-column DNAse I treatment (Qiagen). Both steps were performed according to the manufacturer's instructions. cDNA was synthesized using SuperScript III with random hexamer primers (Invitrogen). RT-qPCR was performed using Fast SYBR Green Master Mix (Thermo Fisher) for host gene expression or TaqMan Master mix (Thermo Fisher) for viral RNA quantification, and reactions performed on the QuantStudio 5 Real-Time PCR systems (Thermo Fisher). Host gene expression was determined using the 2-ΔΔCt method and normalised to GAPDH expression. Viral RNA copies were deduced by standard curve, using primers and a Taqman probe specific for E, as described elsewhere (Corman et al, 2020) and below.

The following primers and probes were used: Target Sequence 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved on a BD Fortessa X20 or LSR II using BD FACSDiva software. Data was analysed using FlowJo v10 (Tree Star).

For detection of ACE2 expression, whole cell protein lysates were separated by SDS-PAGE, transferred onto nitrocellulose and blocked in PBS with 0.05% Tween 20 and 5% skimmed milk.

Membranes were probed with polyclonal goat anti-human ACE2 (1:500, AF933, R&D Biosystems) or rabbit anti-human beat-Actin (1:2500, 6L12, Sigma) followed by donkey anti-goat IRdye 680CW or goat anti-rabbit IRdye 800CW (Abcam), respectively. Blots were Imaged using an Odyssey Infrared Imager (LI-COR Biosciences) and analysed with Image Studio Lite software.

For imaging analysis, Calu-3 or Caco-2 cells were seeded and infected with SARS-CoV-2 in Optical 96well plates (CellCarrier Ultra, PerkinElmer) and cells were fixed with 4% PFA at the indicated timepoints. Permeabilisation was carried out with 0.1% TRITON-X100 (Sigma) in PBS for 15 minutes.

A blocking step was carried out for 1h at room temperature with 10% goat serum/1%BSA in PBS.

Nucleocapsid (N) proten detection was performed by primary incubation with human anti-N antibody (Cr3009, 1ug/ml) for 18h, and washed thoroughly in PBS. Where appropriate, N-protein staining was followed by incubation with rabbit anti-NF-B (p65) (sc-372, Santa Cruz) or rabbit anti-IRF3 (sc-9082, Santa Cruz) for 1 h. Primary antibodies were detected by labelling with with secondary anti-human AlexaFluor488 and anti-rabbit AlexaFluor546 conjugates (Jackson Immuno 

NF-B, IRF3, IL6 and GAPDH raw image channels were pre-processed using a batch rolling ball background correction in FIJI imagej software package (Schindelin et al, 2012) prior to quantification. Cell cytoplasmic area was determined by segmentation of CellMask 647 signal. Intracellular N protein signal was segmented as 'mitochondria' objects. IL-6/GAPDH RNA FISH signal within segmented cells was then quantified. Infected cells were determined by the presence of N protein segmented objects within the cell. Analysis parameters are detailed in Appendix Tables S1-S7.

Statistical analysis was performed using GraphPad Prism. As indicated, normally distributed data was analysed for statistical significance by ttests (when comparing two groups) or one-way ANOVA with

This article is protected by copyright. All rights reserved

Bonferroni or Dunnett's post-test (when comparing more than two groups). Wilcoxon ranked paired non-parametric tests were performed for primary macrophage data that was not normally distributed. For imaging analysis, where appropriate, integrated intensities were normalised to the mean intensity of the mock infected population for that respective timepoint. Comparisons were made using a Kruskal-Wallis test with Dunn's multiple comparison. Data show the mean +/-the S.E.M, where appropriate the median is shown, with significance shown on the figures, levels were defined as *, P < 0.05; **, P < 0.01 and ***, P < 0.001, ****, P < 0.0001.

Conceptualisation:

LGT, AR, LZA, CJ, GJT; Experimental set up, investigation and analysis:

LGT, AR, LZA, MVXW, JT, MN, GJT; Writing, review and editing: all authors.

This study includes no data deposited in external repositories.

The authors have no conflicts of interest to declare. 

This article is protected by copyright. All rights reserved paired t-test comparing MDM exposed to control infected CoM to siMAVS/inhibitor treated infected 

This article is protected by copyright. All rights reserved compared with or without IL1b-treatment, respectively, by unpaired T test (n=3). *, p<0.05; n.s., non-significant. Mean +/-SEM shown. 

This article is protected by copyright. All rights reserved panels for N NF-B and within the IRF3 panels. Horizontal lines indicate the mean. Kruskal-Wallis test with Dunn's multiple comparison, *, p<0.05; **, p<0.01; ***, p<0.001. 

Population-scale longitudinal mapping of COVID-19 symptoms, behaviour and testing

Evidence for camel-to-human transmission of MERS coronavirus

SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients

Accepted Article This article is protected by copyright. All rights reserved

Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Accepted Article This article is protected by copyright. All rights reserved

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

) 5'-Triphosphate RNA is the ligand for RIG-I

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

Cyclophilin A protects HIV-1 from restriction by human TRIM5α

SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. The Lancet Infectious diseases

Francos-Quijorna I et al (2020) A dynamic COVID-19 immune signature includes associations with poor prognosis

Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5

SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes. bioRxiv : the preprint server for biology

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Accepted Article This article is protected by copyright. All rights reserved

Measuring HCV infectivity produced in cell culture and in vivo

ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease. bioRxiv : the preprint server for biology

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB. bioRxiv : the preprint server for biology: 2020

Lung pathology of fatal severe acute respiratory syndrome

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

Genetic mechanisms of critical illness in Covid-19

Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in

2020) Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

HIV-1 evades innate immune recognition through specific cofactor recruitment

SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells

RIG-I detects viral genomic RNA during negative-strand RNA virus infection

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia

Fiji: an open-source platform for biological-image analysis

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Accepted Article This article is protected by copyright. All rights reserved

Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA

Are Evolution and the Intracellular Innate Immune System Key Determinants in HIV Transmission?

Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis. medRxiv : the preprint server for health sciences

SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon

COVID-19: PCR screening of asymptomatic health-care workers at London hospital

Bats, civets and the emergence of SARS

Factors associated with COVID-19-related death using OpenSAFELY

Risk factors for Covid-19 severity and fatality: a structured literature review

Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5

Evasion of Type I Interferon by SARS-CoV-2

MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells

Accepted Article This article is protected by copyright. All rights reserved

CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Accepted Article

This article is protected by copyright. All rights reserved